Exon-skipping drugs for Duchenne muscular dystrophy reach only a fraction of eligible patients
STAT News reports that exon-skipping therapies approved for Duchenne muscular dystrophy — including candidates from Novartis and Dyne — remain inaccessible to most patients who could benefit, testing the FDA's rare-disease drug framework.
A detailed report from STAT News examines the state of exon-skipping therapies for Duchenne muscular dystrophy (DMD), a severe X-linked neuromuscular disorder caused by mutations in the DMD gene encoding dystrophin. Exon-skipping drugs use antisense oligonucleotides to cause the cellular splicing machinery to bypass specific faulty exons, allowing production of a shorter but partially functional dystrophin protein. Different exon-skipping drugs target different subsets of DMD mutations, meaning each approved product is eligible only for a defined proportion of the patient population.
According to the reporting, despite regulatory approvals — granted in part under accelerated and conditional pathways designed to expedite access for rare diseases — relatively few patients are receiving these treatments. Barriers include cost, payer coverage decisions, and the requirement for precise genotyping to confirm mutation eligibility. The article highlights programmes from Novartis and Dyne Therapeutics among those under scrutiny.
The situation is described as a test case for the FDA's broader strategy of using accelerated approval to encourage investment in rare-disease therapeutics. Critics have questioned whether approvals based on surrogate endpoints such as dystrophin protein levels translate to meaningful clinical benefit; proponents argue they create the conditions for further research and market entry. The STAT article is behind a subscription paywall; this summary is based on the published lede and contextual knowledge of the published literature.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Duchenne muscular dystrophy (DMD) is an inherited condition — caused by changes in a gene called DMD — that progressively weakens the muscles. It mainly affects boys and young men. One group of treatments, called exon-skipping drugs, works by helping cells read around the faulty part of the gene, so they can still make a shorter version of an important muscle protein called dystrophin. Some of these drugs have been approved by medicines regulators in the United States. However, a new report describes how very few of the patients who might benefit are actually receiving them, largely because of high costs and questions about what benefit they provide in practice. Researchers and regulators continue to study these treatments to understand their long-term effects.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-07STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few